API Push Trial without Cancer condition at attribute
Study of a Study Medicine After Radiotherapy for H3 K27M-Mutant Diffuse Glioma
Brief description of study
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and
estimate PK parameters for ONC201. To evaluate the efficacy of ONC201
using RANO-LGG criteria. To evaluate the impact of ONC201
treatment on health care resource
utilization.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
The purpose of this research study is to learn about the effects of a study medicine given after radiotherapy in people with H3 K27M-mutant diffuse glioma (a type of brain tumor). The study will also look at how much of the study medicine is in the blood and estimate how the body processes it.
Participants will receive the study medicine after they have radiotherapy. The study team will measure levels of the study medicine in blood (plasma) and will evaluate the tumor using a standard set of criteria for low-grade glioma (RANO-LGG). The study will also track health care resource use during treatment.
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or